Tech Company Financing Transactions
Anthos Therapeutics Funding Round
Anthos Therapeutics, based in Cambridge, received $250 million in investment from Blackstone and Novartis Venture Fund.
Transaction Overview
Company Name
Announced On
2/28/2019
Transaction Type
Venture Equity
Amount
$250,000,000
Round
Undisclosed
Investors
Proceeds Purpose
Anthos Therapeutics will use the investment to advance MAA868, a Novartis antibody drug that is meant to treat blood clots by targeting two clotting proteins, Factor XI and Factor XIa.
Company Information
Company Status
Private & Independent
Industry
Biopharmaceutical
Mailing Address
101 Main St.
Cambridge, MA 02142
USA
Cambridge, MA 02142
USA
Phone
Undisclosed
Website
Email Address
Overview
Anthos Therapeutics is a clinical-stage biopharmaceutical company developing and commercializing innovative therapies for high-risk cardiovascular patients. Anthos is a formation of Blackstone (NYSE: BX) Life Sciences and Novartis AG (NYSE: NVS), one of the worlds' leading pharmaceutical companies.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chairman
Nicholas Galakatos
Chief Executive Officer
John Glasspool
Chief Operating Officer
Jonathan Freeman
VP - Operations
Debra Freedholm
Browse more venture capital transactions:
Prev: 2/28/2019: Obsidian Security venture capital transaction
Next: 2/28/2019: Anitian venture capital transaction
Share this article
About Database of VC Transactions
Our team works diligently to document all VC transactions involving tech companies. VC investment data records on this site are sourced from news reports and company announcements. The data comes to us via our partnership with VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs